Glycocalyx-Edited Stem Cells Cut Fragility Fractures 94% in First-in-Human Osteoporosis Trial
核心洞察
A first-in-human phase 1 trial in Cell infused glycocalyx-edited autologous mesenchymal stromal cells into 10 women with advanced osteoporosis (搜索), with no treatment-related adverse events reported.
Fragility fracture incidence fell from 8 events per year to 0.5 events per year when comparing the two years before and after infusion, a 94 percent reduction.
Bone biopsies at 120 days showed increased average bone tissue area in 7 of 10 patients, and imaging indicated improved trabecular bone density, though DXA showed no significant group-level change.
A first-in-human phase 1 trial has produced early evidence that autologous mesenchymal stem/stromal cells (搜索) (MSCs) engineered to home to bone marrow can reduce fragility fractures in patients with advanced osteoporosis (搜索). The study, reported in Cell and led by first author and hematologist José M. Moraleda of the University of Murcia (搜索) in Spain, treated 10 women aged 51 to 72 with a single intravenous infusion of their own modified MSCs and followed them for a median of approximately six years.
Osteoporosis (搜索) is estimated to affect as many as 500 million people worldwide and to trigger up to 37 million fragility fractures a year, according to the researchers. There is no cure for the progressive bone-weakening disease.
Engineering an Address Label on the Cell Surface
MSCs reside in bone marrow and are the precursors to osteoblasts, the cells that create and repair bone, which makes them a candidate for bone-strengthening therapy. The obstacle is delivery: once MSCs are cultured outside the body and returned intravenously, their lack of a surface molecule called sialylated Lewis X (搜索) (sLeX) limits their ability to reach bone marrow.
The team addressed this through glycocalyx editing. The glycocalyx is the sugary coating on the outside of a cell; the researchers added a sugar called fucose to a molecule called CD44, completing the sialyl Lewis X surface structure. That structure binds E-selectin, a molecule lining specialized blood vessels in bone marrow, effectively acting as a temporary molecular address label that lasts roughly 48 hours, long enough for circulating cells to slow along marrow blood vessels and enter the tissue.
"In preclinical models, this deficit is correctable by MSC glycocalyx editing to enforce sialylated Lewis X (搜索) (sLeX) expression, thereby programming osteotropism," the researchers write. The approach traces back to a 2008 Nature Medicine study in mice in which Robert Sackstein and colleagues showed the same glycan engineering could steer human MSCs into bone marrow.
Trial Design and Dosing
Researchers drew approximately 60 milliliters of bone marrow from each participant's hip, isolated and expanded the MSCs in culture, applied the glycocalyx modification, and delivered the edited cells as a single intravenous infusion. All participants were women aged 51 to 72 with advanced osteoporosis (搜索) who had already sustained osteoporosis-related fractures.
The trial's primary aim was safety. The treatment was well tolerated, with no treatment-related adverse events reported, and no serious adverse events attributable to the cell infusion over the follow-up period.
Fracture Reduction and Bone Findings
The most pronounced signal was in fracture incidence. "Though subjects in this study were clinically at 'very high risk' for recurrent fragility fractures, the refracture incidence dropped precipitously," the authors note. Comparing the two years before infusion with the two years after, fracture incidence fell from 8 events per year to 0.5 events per year, a 94 percent reduction.
Bone tissue biopsies taken 120 days after infusion showed a significant increase in average bone tissue area (BTA) in 7 of the 10 patients. Bone metabolism biomarkers indicated a bone-strengthening effect, and body imaging revealed improvements in the density of spongy trabecular bone. A CT-based measure of trabecular bone quality improved by two years, while conventional DXA bone-density measurements did not show significant group-level improvements.
"Collectively, the results suggest that the administered Fuc-autoBM-MSCs mediate an osteoregenerative effect predominantly within trabecular bone," the researchers write. They note this is a critical issue because trabecular bone is far more metabolically active than cortical bone, and osteoporosis (搜索) predominantly disintegrates trabecular bone early in the disease, with later erosion of cortical bone.
"The results show that this treatment approach has an excellent safety profile and is feasible," the researchers state. "However, strikingly… the results also reveal a durable reduction in the incidence of fragility fractures accompanied by increased serum levels of bone neoformation biomarkers, coupled with radiographic and histomorphometric evidence of an osteorestorative effect within trabecular bone."
Caveats and Next Steps
The authors are explicit that the findings require confirmation. The trial was primarily a safety study and was not a randomized experiment with a control group, so future studies will need to investigate the mechanism further and more formally measure the effects. The researchers also acknowledge the small size of the study, the lack of diversity among participants, and the need for larger studies with broader participant diversity and more study sites.
Independent commentary reflected both the strength of the signal and the limits of the evidence. "It's quite remarkable," Ajit Varki, a physician-scientist at the University of California, San Diego, who was not involved in the research, told Nature. "[The trial] showed an almost 100% efficacy sustained for several years, and no side effects."
Several factors complicate interpretation. Without a randomized control group, the researchers could not determine how much the engineered cells contributed to the fracture reduction. Most participants also received conventional osteoporosis (搜索) treatments, and some changed medications during follow-up. The researchers could not directly track the infused cells inside patients to prove where they localized. A larger randomized trial will be needed to separate these effects.
Sackstein, a study author and a developer of the glycocalyx-engineering approach, holds intellectual-property rights related to the technology under NIH policies.
A Platform Beyond Osteoporosis
The investigators frame the result as a potential shift in treatment strategy. "Precision glycocalyx editing effectuates MSC-based therapy to reverse osteoporosis (搜索), thus potentially shifting therapeutic strategies for this disease from pharmacologic approaches to regenerative medicine," the authors write.
The broader implication concerns cell delivery rather than osteoporosis (搜索) alone. More than 15 years after the approach was first demonstrated in mice, the trial offers early evidence that therapeutic cells can be steered to a chosen tissue without permanently altering their DNA. If that principle holds, targeted "living medicines" could be directed to damaged tissues elsewhere in the body.